Enhancing pharmaceutical leadership performance

Client need 

A global multinational pharmaceutical company was at a critical juncture with the appointment of a new CEO. This leadership change spurred a broader effort to reassess and redefine leadership expectations, aiming to improve operations across the organization. The company sought to evaluate its leaders against these new operational standards and identify strengths and gaps in the organization.

The solution 

The company partnered with BTS to design and implement bespoke 360-assessments for 1,800 senior leaders and 180-assessments for 9,100 people managers with three or more direct reports. These assessments were strategically developed to provide insights at both an individual and global level, thereby aligning leadership performance with the newly articulated corporate goals.

Results  

The initial rollout of the 360-assessment involved approximately 1,800 leaders globally, including 700 executive directors or higher. The success of this phase led to the program’s institutionalization, with the CEO endorsing its annual continuation to support end-of-year performance reviews and broader leadership development. 

Encouraged by the results, the company expanded the initiative to include a 180-assessment, reaching an additional 9,100 people managers. This broader assessment effort cascaded the leadership development strategy down through the managerial ranks, reinforcing the company’s commitment to fostering an inclusive and effective leadership culture. 

The insights gained from these assessments enabled the company to identify where development efforts should be focused, ensuring that leadership across the company is well-equipped to drive future growth and innovation.